ArticleGastrointestinal cancer research : GCR2008
Current approaches to gastric cancer in Korea.
Article in Gastrointestinal cancer research : GCR, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 49 citations in OpenAlex.
- Prevalence and determinants of anemia among individuals with a history of gastric cancer: a nationwide population-based study.BMC public health · 2026Article
- The Present and Future of Neoadjuvant and Adjuvant Therapy for Locally Advanced Gastric Cancer.Cancers · 2023Review
- Gastric Intestinal Metaplasia: Challenges and the Opportunity for Precision Prevention.Cancers · 2023Review
- CD10 and Das1: a biomarker study using immunohistochemistry to subtype gastric intestinal metaplasia.BMC gastroenterology · 2022Article
- A nomogram to predict survival probability of gastric cancer patients undergoing radical surgery and adjuvant chemotherapy.Frontiers in oncology · 2022Article
- Adjuvant Chemotherapy in Node-Negative Advanced Gastric Cancer Patients.Journal of oncology · 2022Article
- Does Delaying Time in Cancer Treatment Affect Mortality? A Retrospective Cohort Study of Korean Lung and Gastric Cancer Patients.International journal of environmental research and public health · 2021Article
- Identification of Novel Autoantibodies Based on the Human Proteomic Chips and Evaluation of Their Performance in the Detection of Gastric Cancer.Frontiers in oncology · 2021Article
- Comparison of S-1 plus oxaliplatin (SOX) and capecitabine plus oxaliplatin (XELOX) as adjuvant chemotherapies for stage II and III gastric cancer after D2 resection: A single-center retrospective study.Asia-Pacific journal of clinical oncology · 2020Article
- Oncometabolic surgery: Emergence and legitimacy for investigation.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2020Article
- Article
- Using recursive partitioning approach to select tumor-associated antigens in immunodiagnosis of gastric adenocarcinoma.Cancer science · 2019Article
- Recent updates in perioperative chemotherapy and recurrence pattern of gastric cancer.Annals of gastroenterological surgery · 2018Review
- Identification of a high-risk subtype of intestinal-type Japanese gastric cancer by quantitative measurement of the luminal tumor proportion.Cancer medicine · 2018Article
- Adjuvant chemotherapy with S-1 plus oxaliplatin improves survival of patients with gastric cancer after D2 gastrectomy: A multicenter propensity score-matched study.World journal of clinical cases · 2018Article
- The composition and variation of the BCR CDR3s in gastric cancer.Oncology letters · 2018Article
- Screening and Identification of Peptides Specifically Targeted to Gastric Cancer Cells from a Phage Display Peptide LibraryAsian Pacific journal of cancer prevention : APJCP · 2018Article
- Outcomes of radiation therapy for resectable M0 gastric cancer.Oncotarget · 2018Article
- Efficacy and safety of trastuzumab as maintenance or palliative therapy in advanced HER2-positive gastric cancer.OncoTargets and therapy · 2018Article
- Development and external validation of preoperative risk models for operative morbidities after total gastrectomy using a Japanese web-based nationwide registry.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric cancer remains a significant global health problem and is the most common cancer in Korea. Surgery is the only curative treatment for localized gastric cancer, but most cases present at an advanced stage. The proportion of early gastric cancer and the incidence of gastric cancer located in the upper third of the stomach have increased in Korea. The majority of patients in Korea receive surgery alone or surgery plus chemotherapy. Over 50% of the surgeries have been performed in five major hospitals, with most surgeons performing extended lymph node dissection (D2 or D3). The 5-year survival rate with curative resection is 55.6%-66.0%, with rates of 92.9%-98.0%, 84.2%-92.0%, 69.3%-72.0%, 45.8%-54.0%, 29.6%-36.5%, and 9.2%-23.9% according to TNM stages of Ia, Ib, II, IIIa, IIIb, and IV, respectively. Although convincing phase III data are lacking, postoperative immunochemotherapy with 5-fluorouracil (5-FU) plus mitomycin for 2 months followed by OK-432 plus doxifluridine for 24 months has been widely used in Korea. A phase III trial of adjuvant capecitabine/oxaliplatin is ongoing in curatively resected disease (CLASSIC study). The modified 5-FU/cisplatin regimen has become popular since the mid 90s, and various combinations including taxanes, oral 5-FU prodrugs, oxaliplatin, and irinotecan have been evaluated. Recently, Korean investigators have played pivotal roles in studies initiated by global pharmaceutical companies, and the Korean Cancer Study Group has initiated 14 multicenter trials, including phase III trials in gastric cancer and international cooperative trials. Future international cooperative trials are anticipated.
Identifiers
19259291PMC2633072W2415212931What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.